5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro

Abstract The coronavirus disease 2019 (COVID 19) pandemic continues to pose a threat to global health. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) has spread rapidly worldwide and became dominant in many countries. A natural 5-aminolevulinic acid (5-A...

Full description

Bibliographic Details
Published in:Tropical Medicine and Health
Main Authors: Mya Myat Ngwe Tun, Takaya Sakura, Yasuteru Sakurai, Yohei Kurosaki, Daniel Ken Inaoka, Norifumi Shioda, Chris Smith, Jiro Yasuda, Kouichi Morita, Kiyoshi Kita
Format: Article in Journal/Newspaper
Language:English
Published: BMC 2022
Subjects:
SARS-CoV-2
Omicron variant
5-ALA
SFC
Antiviral activity
Arctic medicine. Tropical medicine
RC955-962
Arctic
Online Access:https://doi.org/10.1186/s41182-022-00422-7
https://doaj.org/article/1aef327c968242ceab8ca1da7f3975c1
Description
Summary:Abstract The coronavirus disease 2019 (COVID 19) pandemic continues to pose a threat to global health. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) has spread rapidly worldwide and became dominant in many countries. A natural 5-aminolevulinic acid (5-ALA) with sodium ferrous citrate (SFC) has demonstrated antiviral activity in Wuhan, Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 infections in vitro. In this study, we report antiviral activity of 5-ALA, 5-ALA with SFC led to IC50 of 329 and 765/191, respectively after infection with Omicron variant of SARS-CoV-2 in vitro. Our finding suggests that 5-ALA could be used as antiviral drug candidate to treat Omicron variant infected patients.

Similar Items